Biogen Idec, a large biotechnology company based in Weston, Mass., said it has agreed to buy Stromedix, a privately held biotechnology company focused on therapies for fibrosis and organ failure.
Biogen, Stromedix strike deal worth up to $562 million
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.